Abstract: Hypotensive mammals are treated to lower mean blood pressure by administering synergistic amounts of a calcium blocking agent together with a calcium supplement.
Type:
Grant
Filed:
April 9, 1997
Date of Patent:
March 23, 1999
Assignee:
Peter K. T. Pang
Inventors:
Peter K. T. Pang, Richard Z. Lewanczuk, Christine G. Benishin, Jie Shan
Abstract: A kit containing benzeneacetonitrile and calcium or dihydropyridine and calcium hypertensive mammals may be treated to lower mean blood pressure by administering a calcium channel blocking agent together with one or both of a calcium supplement and Vitamin D. The hypotensive effect of this combination is synergistic and the dose response is more predictable than the administration of any of these agents singly.
Type:
Grant
Filed:
June 22, 1994
Date of Patent:
October 10, 1995
Assignee:
Peter K. T. Pang
Inventors:
Peter K. T. Pang, Richard Z. Lewanczuk, Christine G. Benishin
Abstract: Hypertensive mammals may be treated to lower mean blood pressure by administering a calcium channel blocking agent together with one or both of a calcium supplement and Vitamin D. The hypotensive effect of this combination is synergistic and the dose response is more predictable than the administration of any of these agents singly.
Type:
Grant
Filed:
July 27, 1992
Date of Patent:
October 11, 1994
Assignee:
Peter K. T. Pang
Inventors:
Peter K. T. Pang, Richard Z. Lewanczuk, Christine G. Benishin
Abstract: Hypertensive mammals may be treated to lower mean blood pressure by administering a calcium channel blocking agent together with one or both of a calcium supplement and Vitamin D. The hypotensive effect of this combination is synergistic and the dose response is more predictable than the administration of any of these agents singly.
Type:
Grant
Filed:
December 28, 1992
Date of Patent:
September 27, 1994
Assignee:
Peter K. T. Pang
Inventors:
Peter K. T. Pang, Richard Z. Lewanczuk, Christine G. Benishin
Abstract: Analogues of bovine and human parathyroid hormone, wherein twenty-fifth, twenty-six and twenty-seventh positions of the natural hormone, Arg-Lys-Lys- each have been substituted with Ala, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val have been found to retain bone cell effect with minimal effects on blood pressure and smooth muscle, including cardiac muscle. It has further been found that this effect can be obtained by using a synthetic PTH containing only the first 34 amino acids of PTH, with substitution at the twenty-fifth, twenty-sixth and twenty-seventh amino acids as described. These analogues of PTH also are effective in the treatment of osteoporosis and other bone diseases.
Abstract: A new circulating factor from the parathyroid gland of some hypertensive mammals have been isolated and characterized. Polyclonal and monoclonal antibodies raised against this factor are usable as a screen for the presence of the factor. The factor is involved in the control of calcium uptake in cells. Hypertensive mammals may be treated to lower mean blood pressure by administering a calcium channel blocking agent together with one or both of a calcium supplement and Vitamin D. The hypotensive effect of this combination is synergistic and the dose response is more predictable than the administration of any of these agents singly. The factor has a molecular weight of 3,000 to 4,000 Daltons.
Type:
Grant
Filed:
November 21, 1990
Date of Patent:
March 9, 1993
Assignee:
Peter K. T. Pang
Inventors:
Peter K. T. Pang, Richard Z. Lewanczuk, Christine G. Benishin, Toyoii Kaneko